Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus EPIFOAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus EPIFOAM.
CAPEX vs EPIFOAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Epinephrine is a sympathomimetic amine that acts as a non-selective agonist at alpha- and beta-adrenergic receptors. It causes vasoconstriction, bronchodilation, and increased heart rate and contractility.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Not applicable; EPIFOAM is a topical foam containing pramoxine hydrochloride 1% and aluminum acetate, used for hemorrhoidal symptoms. No systemic dosing.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
2-3 hours (terminal elimination half-life); clinically, this supports every 4-6 hour dosing intervals for consistent effect.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily hepatic metabolism to inactive glucuronide conjugates; renal excretion of metabolites accounts for ~80% of elimination, with ~15% biliary/fecal. Less than 5% excreted unchanged in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid